FDA grants Monoamine Oxidase Deficiency Orphan Drug Designation
GALVESTON, Texas, June 15, 2026 /PRNewswire/ -- Families affected by monoamine oxidase deficiency (MAOD), a rare neurodevelopmental disorder, have historically faced delayed diagnosis, limited clinical guidance and scant treatment options. MAOD is an X-linked genetic condition caused by...
GALVESTON, Texas, June 15, 2026 /PRNewswire/ -- Families affected by monoamine oxidase deficiency (MAOD), a rare neurodevelopmental disorder, have historically faced delayed diagnosis, limited clinical guidance and scant treatment options. MAOD is an X-linked genetic condition caused by...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.